Day: January 28, 2022

Proceeds Allocated to Development of Recently Acquired mRNA Biomarkers and Launch of Clinical Studies to Support ColoAlert’s FDA Submission BERKELEY, Calif. and MAINZ, Germany, Jan. 28, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the closing of its underwritten public follow-on offering (the “Follow-on Offering”) of 1,725,000 ordinary shares at a public offering price of US$15.00 per ordinary share (the “Offering Price”). The aggregate gross proceeds to Mainz Biomed were $25,875,000 before deducting underwriting discounts and commissions and other offering expenses payable. This included the exercise in full by the underwriters of their option to purchase 225,000 additional shares...

Old Bethpage, NY, Jan. 28, 2022 (GLOBE NEWSWIRE) — Power REIT (“Power REIT,” “we,” “our,” or the “Company;” NYSE American: PW and PW.PRA), today announced the estimated Federal income tax treatment of the Company’s 2021 distributions on its 7.75% Series A Preferred Stock (CUSIP # 73933H200).  The Federal income tax classification of the distribution per share on the Company’s 7.75% Series A Preferred Stock with respect to the calendar year ended December 31, 2021 is shown in the table below:RecordDate PayableDate TotalDistributionPer Share OrdinaryIncomePer Share Return ofCapitalPer Share Capital GainPer Share2/15/21 3/15/21 $0.484375 $0.484375 $0.0 $0.005/15/21 6/15/21 $0.484375 $0.484375 $0.0 $0.008/15/21 9/15/21 $0.484375 $0.484375 $0.0 $0.0011/15/21 12/15/21 $0.484375 $0.484375 $0.0 $0.00           Nothing...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Hampton Financial Corporation (“Hampton” or the “Company”, TSXV:HFC & HFC.PR.A) today announced its financial results for the 1st quarter ended November 30th, 2021. “The first quarter results represent another record performance since becoming a public company and demonstrate the continued progress we are making in growing our business. Our strategy for growth and streamlining our business model continues to show results across all business lines,” said Hampton Executive Chairman & CEO Peter Deeb. “We enter a new fiscal year with a strong start, a solid pipeline of equity capital market activity and further growth in our Wealth Management business. We want to thank our loyal clients for their...

Casino Group communication Paris, 28th January 2022, In Q4 2021, the French food retail market conjuncturally declined at a higher rate than expected, by -3.7% at country level, and -5.6% in Ile de France1. In this context, the Group adjusts its guidance announced on 4 November 2021 for its retail banner scope in France2 (“EBITDA growth for 2021”) and now expects a slight decrease in 2021 EBITDA on that perimeter of -1.7% to around €1,280m3 vs €1,304m in 2020. Casino Group will disclose its Q4 trading and 2021 annual results on 25 February 2022. Important Information This press release and the information contained herein does not constitute an offer to repurchase the bonds or an invitation to sell the bonds or an invitation to participate in such an offer to repurchase in, or from, any country in or from which, or from or to any person...

VANCOUVER, BC, Jan. 28, 2022 (GLOBE NEWSWIRE) — NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave”) (CSE: SPOR) (FWB: 0XMB) (OTCPK: TRMNF) an investment issuer that provides capital and support services, is pleased to provide an update to its spin-out transaction (the “Spin-out Transaction”) announced on May 21, 2021. Its wholly-owned subsidiary, Way of Will Inc. (“WoW”) has now received final approval from the Canadian Securities Exchange (the “CSE”) and the Company’s Class A common shares will commence trading on the CSE on January 31, 2022 under the symbol “WAY”.   For further information concerning Way of Will Inc. and its business, please see the long form prospectus dated December 13, 2021 (the “Prospectus”) supporting its application for listing on the CSE. A copy of the Prospectus was filed under...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 28, 2022 (GLOBE NEWSWIRE) — G2 Goldfields Inc. (“G2” or the “Company”) (TSXV:GTWO; OTCQX:GUYGF) announces that it has closed the second and final tranche (the “Second Tranche”) of its previously announced non-brokered private placement (the “Offering”). In connection with the closing of the Second Tranche of the Offering, the Company sold 4,550,000 units of the Company (the “Units”) at a price of $0.45 per Unit, for gross proceeds of $2,025,000. As a result, the Company sold a total of 6,800,000 Units pursuant to the Offering (including the first tranche, which closed on January 6, 2022), for gross proceeds of $3,060,000. Each Unit consisted of one common share (“Share”) of the Company and one common share purchase warrant (“Warrant”)....

CORAL GABLES, Fla., Jan. 28, 2022 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today reported that the U.S. Court of Appeals for the 11th Circuit has issued a mandate directing the District Court that heard Catalyst’s claim against the FDA to enter summary judgment in favor of Catalyst in its lawsuit against the FDA, thereby vacating the FDA’s approval of Ruzurgi® (Jacobus Pharmaceutical Company’s amifampridine product). Patrick J. McEnany, Catalyst’s Chairman and CEO stated: “Catalyst’s priority has always been, and will continue to be, to put patients’ needs first, and...